pancreatic NET
Oncology · 2011–2012
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sunitinib malate Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pancreatic NET) in patients who… | Jul 2012 | Recommended | unclear |
| sunitinib malate Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pancreatic NET) in patients who… | Mar 2012 | Deferred | no section in document |
| sunitinib malate Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour in patients who are symptomatic… | Mar 2012 | Deferred | no section in document |
| sunitinib malate Initial and continuing treatment of unresectable, well-differentiated pancreatic neuroendocrine tumour (pNET) in patients who are unsuitable for cytotoxic… | Jul 2011 | Not recommended | no section in document |
What the PBS pays
$4M in government benefit over 2024–25, across 1,904 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sunitinib | $3.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.